Alivus Life Sciences Ltd

Meeting Details

• Aug 28, 2026 — Mirae Asset (US): Virtual, One-on-One investor meeting.
• Sept 1, 2026 — Emkay Global: In-person, Mumbai, One-on-One.
• Sept 1, 2026 — SIMPL: In-person, Mumbai, One-on-One.
• Sept 2, 2026 — Lyptus Capital: Virtual, One-on-One.

Participants

• Key company participant: Company Secretary & Compliance Officer.

Purpose

• Intimation of Investors/Analyst meetings with external investors and analysts.

Deal details

• Alivus Life Sciences to acquire 76% stake in IQGenX Pharma Private Limited for INR 91.2 million.

Deal timing

• Acquisition subject to customary closing conditions; expected to close by end of the current calendar year.

Strategic rationale

• Expands formulation development capabilities and global CDMO footprint with IQGenX platform.

Platform capabilities

• Bioequivalence and stability studies, pre-formulation, scale-up, regulatory submissions support.

Integration plan

• IQGenX to complement Alivus' oncology API portfolio and enable out-licensing across geographies.

Financials and ownership

• Total consideration INR 91.2 million for 76% stake.

Operational footprint

• IQGenX founded in October 2016; CRO working in regulated markets worldwide.

Regulatory readiness

• Alivus has four facilities with 1,424 KL installed capacity; inspected by USFDA, PMDA, EDQM.

Outlook

• Acquisition to broaden global customer base in the generic pharma segment.

Target & deal terms

• IQGEN-X Pharma Private Limited, Indian pharma company engaged in formulation development.
• Aggregate cash consideration INR 9.12 crore for 8,60,589 shares, 76% stake.
• Completion targeted by December 6, 2026, subject to conditions precedent.
• No promoter/group interest; acquisition not a related party transaction.

Strategic rationale

• Enables end-to-end API and CDMO solutions for customers.
• Strengthens Alivus' portfolio in pharmaceuticals.

Regulatory & timeline

• No government or regulatory approvals required.

Target background

• Incorporated Oct 2016; based in Navi Mumbai, India.
• Industry: Pharmaceuticals; focuses on formulation development.
• Products: formulation development for Oral Solids, Sterile Injectables, Ophthalmic solutions.
• Turnover history: 2023-24 Rs 267.5 Lacs; 2024-25 Rs 318.2 Lacs; 2025-26 Rs 348.0 Lacs.

Meeting Details

• Aug 18, 2026 — Green Lantern Capital — In-person, Mumbai — One-on-One
• Aug 18, 2026 — SIMPL — In-person, Mumbai — One-on-One
• Aug 19, 2026 — Burman Capital — Virtual — One-on-One
• Aug 19, 2026 — Karma Capital — In-person, Mumbai — One-on-One

Participants

• Company management to participate in all four one-on-one meetings

Purpose

• One-on-one investor/analyst discussions

Overview

• API manufacturer reporting on a standalone basis for FY2025-26.
• 90% of turnover derives from APIs with 75+ international markets.
• Exports represented 54.4% of turnover.

Key ESG Risks & Opportunities

• Talent recruitment, development, retention risk mitigated via structured programs and AI feedback.
• Supply chain disruption risk addressed through close supplier collaboration and monitoring.
• Counterfeit drugs risk mitigated by strict QC and robust traceability.
• Access to medicines opportunity via pricing strategies improving affordability.
• Carbon neutrality by 2030 and water neutrality by 2027 targeted.
• External assurance on Core KPIs adds credibility.

Governance & Policy Highlights

• Board oversight with a dedicated ESG Committee.
• Policies include anti-bribery, whistle-blower, human rights, Code of Conduct, Supplier Code.
• BSI provided limited assurance on Core KPIs for FY2025-26.
• Sept 30, 2025 Ankleshwar plant fire led to ₹29 lakh penalty; ₹10 lakh bank guarantee.
• Independent external assessments conducted by Dhir & Dhir Associates.

Social Responsibility & Workforce

• Total employees 2,284; permanent 2,272; workers 1,666; board female representation 14%.
• LTIFR: employees 2.01; workers 1.70; injuries 9 employees and 12 workers; 2 fatalities total.
• ISO 45001/ISO 14001; GMP ANVISA; 23,951 training hours for employee development.
• CSR programs Sampurna and ViGyasa benefited about 213k people; 35,000 trees planted.

Environmental Performance

• Total energy 827,183 GJ; renewables ~62% of energy use.
• GHG emissions: Scope 1 4,284.9 tCO2e; Scope 2 58,030.7 tCO2e; Scope 3 86,669 tCO2e (limited).
• Water withdrawal 367,994 KL; water consumption 342,188 KL; RO reuse and ETP/RO approach.
• Total waste 16,391 MT; major wastes include plastics 777.85 MT and ETP sludge 728.44 MT.

Stakeholder Engagement & Complaints

• Customers filed 47 complaints in FY2025-26; 8 pending at year-end.
• Investors filed 2 complaints; all resolved; formal channels include CX and RTA.
• Communities engaged via need assessments and CSR programs with baseline and impact studies.

Other Notable Metrics

• Life Cycle Assessment conducted for Azelaic Acid (3% of turnover) by Goldfinch Eng System.
• MSME input share 38%; 61% inputs sourced within India.
• Related party transactions: 2025-26 purchases 0%; sales 0.02% of total; 2024-25 sales 34.80%.
• Cybersecurity framework with IT Acceptable Usage Policy; no data breaches reported.

Financials

• Revenue from operations ₹25,518 mn; up 6.9% YoY.
• EBITDA ₹8,577 mn; margin 33.6%.
• Net profit ₹5,645 mn; Basic EPS ₹45.99.
• Total income ₹26,122 mn; up 7.9%.
• Dividend proposed ₹5/share; 250% payout; approx ₹613.41 mn cash outflow if approved.
• Net debt-free; cash ₹7,824 mn at year-end.
• Cash flow from operations ₹5,654 mn; capex ₹3,071 mn.
• ROCE ~22.5%, ROE ~18.4%, ROIC ~30.2%.

Portfolio & Growth

• 176 APIs in portfolio across CVS, CNS, Diabetes, Oncology, Urology, Pain.
• HPAPI portfolio: 28 products; TAM USD 73 bn; 12 validated, 7 advanced, 9 lab.
• 611 global DMF/CEP filings; 900+ customers in 75+ countries.
• CDMO growth: 18% YoY; non-GPL share rising; oncology pipeline advancing.
• Solapur greenfield API facility; phase 1 adds 465 KL; total capacity targeted 2,690 KL by FY29.
• New R&D center at Talolja (Navi Mumbai) to support API and CDMO growth.
• FY26: four manufacturing facilities with USFDA/other regulator inspections; Ankleshwar first continuous process.

Capital & Dividends

• Equity capital ₹245.47 mn; 199,296 shares issued on ESOP exercise.
• Promoter holding (Nirma) 74.87%.
• ESOP outstanding 545,631 options; 199,296 exercised in FY26.
• Dividend ₹5 per share; 250% payout; annual AGM approval required.
• Net debt-free; cash ₹7,824 mn; no borrowings.

Governance & Management

• Board of 7 directors: 2 Exec, 1 Non-Exec, 4 Independent; ESG Committee in place.
• Independent Directors Manju Agarwal and T. L. Easwar reappointed for 5-year terms.
• Auditors: Walker Chandiok; Secretarial: Bhadresh Shah; Cost Auditor: Kirit Mehta & Co.
• Four Board meetings in FY26; Independent Directors met separately in Jan 2026.
• Integrated Report and BRSR core assurance provided by BSI; governance framework disclosed.

ESG & Sustainability

• BSI provided limited assurance on BRSR Core KPIs; scope includes GHG, water, energy, wellbeing, diversity, inclusion, openness.
• 63% energy from renewables; water intensity 0.36 KL/kg; water use 342,187 KL; 1,85,809 KL water recycled.
• 39,000 trees planted; total trees planted 1,15,600 with 1,43,400 tCO2 sequestration over lifespan.
• NPWI water credits being pursued with TÜV SÜD; ESG governance and ongoing training in safety and human rights.
• CSR spend ₹129.69 mn; beneficiaries ~3.61 lakh; Sampurna and ViGYASA impactful education and healthcare programs.

Operations & Manufacturing

• Four MP facilities: Ankleshwar 950 KL, Dahej 400 KL, Mohol 49 KL, Kurkumbh 25 KL.
• Solapur API facility: Phase 1 465 KL; total capacity target 2,690 KL by FY29.
• First continuous manufacturing at Ankleshwar; one global product launched; Dahej modules commissioned.
• Regulatory inspections: 56 across facilities; USFDA inspections at key sites.
• Global CDMO growth complements core API with HPAPI and advanced manufacturing capabilities.

CSR & Stakeholders

• CSR spend ₹96.02 mn; shortfall ₹31.79 mn; shortfall deposited ₹33.67 mn toward ongoing projects.
• Flagship programs Sampurna (healthcare) and ViGYASA (education); beneficiaries in lakhs across communities.
• Community development and environmental sustainability projects including water harvesting, solar irrigation, and forestation.
• Stakeholder engagement channels include customers, employees, suppliers, investors, and communities; regular reporting via AGM and website.
• Independent CSR impact assessments conducted; Net Positive Water initiative and environmental governance embedded in strategy.

AGM Details

• AGM date/time: 8 September 2026 at 3:00 PM IST via VC/OAVM.
• Cut-off date for voting eligibility: 1 September 2026.
• Remote e-voting window: 4–7 September 2026 (9:00 AM–5:00 PM IST).
• Deemed venue: Corporate Office of the company.

Resolutions Proposed

• Adopt Audited Financial Statements for FY 2025-26.
• Declare final dividend of Rs 5 per equity share.
• Re-appoint Hiren Patel as Non-Executive Director, liable to retire by rotation.
• Ratify Cost Auditors' remuneration for FY 2027: Rs 0.50 million plus taxes and expenses.

Voting Status

• Outcome of resolutions not disclosed in this notice.

Meeting Details

• Date: August 12, 2026.
• Mode: In-person.
• Place: Mumbai.
• Type: Group/One-on-One.
• Organizer: Emkay Confluence Conference.

Participants

• Company representatives (management) will attend.

Purpose

• Purpose: investor/analyst interaction.

Meeting Details

• Date: July 31, 2026; Time: not disclosed
• Type: Group conference call
• Mode: Virtual
• Event: Q1 FY27 Earnings Call organized by Alivus Life Sciences Limited

Participants

• Managing Director & Chief Executive Officer (present)
• Chief Financial Officer (present)
• Senior General Manager, Investor Relations (host)

Purpose

• Discuss Q1 FY27 earnings results and outlook with investors

Availability

• Recording of the call and transcript will be available on the company website
• Presentation materials also hosted on the website